BARNES-JEWISH HOSPITAL
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
About Us
News & Events
Maps & Locations
Contact Us
Google Search
PATIENT AND VISITOR INFORMATION
TREATMENT PROGRAMS
PREVENTION AND SCREENING
RESEARCH
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Home
Treatment Programs
Types of Cancer
Clinical Trial Search Results
Share
Lymphoma
NCI Information
Clinical Trials
Non-Hodgkin Lymphoma Trials
Hodgkin Lymphoma Trials
Bone Marrow Transplant (BMT) Trials
Support Groups
Effects of Treatment
Patient Stories
Bone Marrow and Stem Cell Transplantation
Treatment Team
NEW SEARCH
RETURN TO SEARCH RESULTS
Number:
201207089
Principal Investigator:
Bartlett, Nancy
Title:
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase:
III
Disease Site:
Multiple Sites
Participating Site(s):
Main Campus
Map and Directions
Contact:
800-600-3606 or
info@ccadmin.wustl.edu
Description:
The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
More Information:
(Links will take you off this web site)
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)